Download Supplemental Table 1: Reported organ and tumor specific markers

Supplemental Table 1: Reported organ and tumor specific markers in various
cancer types
Antigen (Biomarker)
CEA
EGFR
PSA
HER-2
MUC-1
EPHB4
IGF-1R
Cadherin-11
CSV
Type of cancer
Breast, Gastric, Pancreatic
Colon, Breast, Gastric
Prostate
Breast, Gastric
Colorectal, Ovarian, Breast, Prostate
Breast, Colorectal, Head & Neck
Prostate
Breast, Prostate
Sarcoma
References
[1, 2]
[2-4]
[5]
[6, 7]
[8-10]
[11, 12]
[13] [14]
[15]
[16]
1. Stathopoulou A, Mavroudis D, Perraki M, Apostolaki S, Vlachonikolis I, Lianidou E, et al.
Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of
CK-19, CEA and maspin as detection markers. Anticancer Res 2003; 23:1883-90.
2. Lankiewicz S, Rother E, Zimmermann S, Hollmann C, Korangy F, Greten TF. Tumour-associated
transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and
circulating tumour cells. Cell Oncol 2008; 30:463-71.
3. Payne RE, Yagüe E, Slade MJ, Apostolopoulos C, Jiao LR, Ward B, et al. Measurements of EGFR
expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients.
Pharmacogenomics 2009; 10: 51-7.
4. Dragovich T, Campen C. Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An
Evolving Concept. J Oncol 2009; 2009:804108.
5. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L et al. Isolation and characterization of
circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med
2010; 2: 25ra23.
6. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, et al. Correlation of HER2 status
between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.
Breast Cancer Res Treat 2009; 118: 523-30.
7. Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, et al., Isolation of breast cancer
and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip
2104; 14:147-56.
8. Cheng JP, Yan Y, Wang XY, Lu YL, Yuan YH, Jia J, Ren J. MUC1-positive circulating tumor cells
and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer. Chin
J Cancer. 2011; 30: 54-61.
9. Hardingham J, Hewett PJ, Sage RE, Finch JL, Nuttall JD, Kotasek D, et al., Molecular detection of
blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J
Cancer 2000; 89:8-13.
10. O'Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG, Terstappen LW. Multigene reverse
transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem
2004; 50: 826-35.
11. Winter SC, Stephenson SA, Subramaniam SK, Paleri V, Ha K, Marnane C, et al. Long term survival
following the detection of circulating tumour cells in head and neck squamous cell carcinoma. BMC
Cancer 2009; 9: 424.
12. Raynor M, Stephenson SA, Pittman KB, Walsh DC, Henderson MA, Dobrovic A. Identification of
circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.
J Hematol Oncol 2009; 2: 24.
13. Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in
cancer management and predicting outcomes. Ther Adv Med Oncol 2010; 2: 351-65.
14. de Boneo JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, et al. Potential applications for
circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007; 13:
3611-6.
15. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, et al. Circulating
tumor cells from patients with advanced prostate and breast cancer display both epithelial and
mesenchymal markers. Mol Cancer Res 2011. 9: 997-1007.
16. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, et al. Universal marker and detection
tool for human sarcoma circulating tumor cells. Cancer Res 2014; 74:1645-50.